MX2009004439A - Composicion de ibuprofeno. - Google Patents

Composicion de ibuprofeno.

Info

Publication number
MX2009004439A
MX2009004439A MX2009004439A MX2009004439A MX2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A MX 2009004439 A MX2009004439 A MX 2009004439A
Authority
MX
Mexico
Prior art keywords
water
soluble acid
ibuprofen composition
ibuprofen
water soluble
Prior art date
Application number
MX2009004439A
Other languages
English (en)
Inventor
Robert Shen
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of MX2009004439A publication Critical patent/MX2009004439A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

La invención se refiere a una tableta de liberación inmediata capaz de ser masticada o desintegrada en la cavidad oral, que comprende una pluralidad de partículas en una matriz; las partículas contienen un ingrediente activo, tal como ibuprofeno, y un primer ácido soluble en agua que tiene una solubilidad mayor que aproximadamente 10 g/100 ml de agua a 20°C; y la matriz contiene un segundo ácido soluble en agua que tiene una solubilidad menor que aproximadamente 5 g/100 ml de agua a 20°C.
MX2009004439A 2006-10-25 2007-10-24 Composicion de ibuprofeno. MX2009004439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434906P 2006-10-25 2006-10-25
PCT/US2007/082348 WO2008052033A2 (en) 2006-10-25 2007-10-24 Ibuprofen composition

Publications (1)

Publication Number Publication Date
MX2009004439A true MX2009004439A (es) 2009-05-11

Family

ID=39223093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004439A MX2009004439A (es) 2006-10-25 2007-10-24 Composicion de ibuprofeno.

Country Status (8)

Country Link
US (1) US20080113021A1 (es)
EP (1) EP2094248A2 (es)
CN (1) CN101528205A (es)
AU (1) AU2007308986A1 (es)
BR (1) BRPI0718428A2 (es)
CA (1) CA2667207A1 (es)
MX (1) MX2009004439A (es)
WO (1) WO2008052033A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2853262T3 (en) 2009-10-26 2017-03-06 Sephoris Pharmaceuticals Llc Treatment of sunburn using analgesics and antihistamines
WO2012056471A2 (en) * 2010-10-24 2012-05-03 Shasun Pharmaceuticals Limited Novel process for preparing dexibuprofen ready to compress granules
CN102258490B (zh) * 2011-07-01 2012-10-03 中美天津史克制药有限公司 布洛芬咀嚼片
JP6122427B2 (ja) 2011-07-07 2017-04-26 ヤンセン・サイエンシズ・アイルランド・ユーシー ダルナビル複合製剤
CN102488681B (zh) * 2011-12-21 2013-03-13 西南大学 布洛芬苯海拉明口腔崩解片及其制备方法
CA2884119A1 (en) 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Low melting propionic acid derivative particles for use in oral dosage forms
RU2015114433A (ru) * 2012-09-18 2016-11-10 МакНЕЙЛ-ППС, ИНК. Пероральные дозированные формы с замедленным высвобождением, содержащие частицы легкоплавкого производного пропионовой кислоты
ES2946985T3 (es) * 2013-03-14 2023-07-31 Redhill Biopharma Ltd Formas farmacéuticas sólidas antieméticas de liberación prolongada
WO2015136377A2 (en) 2014-03-11 2015-09-17 Redhill Biopharma Ltd. Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
WO2015157729A1 (en) * 2014-04-11 2015-10-15 Wilmink Michael Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant
ES2926494T3 (es) 2015-03-26 2022-10-26 Sen Jam Pharmaceutical Llc Combinación de naproxeno y fexofenadina para inhibir los síntomas asociados con veisalgia
RU2744270C2 (ru) * 2015-12-28 2021-03-04 ЭсЭсПи КО., ЛТД., ДЖАПАН Прессованный фармацевтический препарат
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
TW202045153A (zh) 2019-02-22 2020-12-16 英商康泰倫特英國斯文敦載迪斯有限公司 含伊布洛芬之醫藥組合物之塗層之黏聚最小化、通氣及保存
CA3129434A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
HUE064524T2 (hu) * 2019-02-22 2024-03-28 Catalent Uk Swindon Zydis Ltd Szuszpenziók aerálódásának minimalizálása in-line keverés során
MX2021009844A (es) 2019-02-22 2021-09-10 Catalent Uk Swindon Zydis Ltd Conservacion de particulas de ingredientes farmaceuticos activos revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspension acuosa.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54127247A (en) * 1978-03-27 1979-10-03 Toshiba Corp Microprogram controller
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
DE3440288A1 (de) * 1984-11-05 1986-05-07 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische zubereitung mit einem gehalt an mindestens einer schleimhautreizenden substanz oder dergleichen, insbesondere profen, sowie verfahren zu ihrer herstellung
US4802924A (en) * 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US4867983A (en) * 1987-02-20 1989-09-19 Mcneilab, Inc. Method for double dipping gelating coated caplets
US4966771A (en) * 1987-02-20 1990-10-30 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
AU674840B2 (en) * 1992-01-17 1997-01-16 Bpsi Holdings, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5466865A (en) * 1993-07-02 1995-11-14 Ibah, Inc. Neomorphic ibuprofen and methods of using same
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6274162B1 (en) * 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US6440983B1 (en) * 2000-12-21 2002-08-27 Mary Theresa Frank-Kollman Compositions and methods for relieving headache symptoms in aspirin-sensitive headache sufferers
AU2002244865A1 (en) * 2001-03-02 2002-09-19 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition of ibuprofen
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US6982094B2 (en) * 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
BR0206062A (pt) * 2001-09-28 2004-01-13 Mcneil Ppc Inc Formas de dosagem tendo um núcleo interno e invólucro externo
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
AU2006312119B2 (en) * 2005-11-02 2010-04-29 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same

Also Published As

Publication number Publication date
US20080113021A1 (en) 2008-05-15
AU2007308986A1 (en) 2008-05-02
CA2667207A1 (en) 2008-05-02
EP2094248A2 (en) 2009-09-02
BRPI0718428A2 (pt) 2013-11-12
WO2008052033A3 (en) 2008-06-12
CN101528205A (zh) 2009-09-09
WO2008052033A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
MX2009004439A (es) Composicion de ibuprofeno.
EP3492069A3 (en) Pharmaceutical compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
IL179718A0 (en) Pharmaceutical composition containing irbesartan
MY147641A (en) Fast release paracetamol tablets
AU2010308458A8 (en) Orally transformable tablets
MX343358B (es) Tabletas de acetato de ulipristal.
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
WO2010033726A3 (en) Drug delivery composition comprising a self-assembled gelator
AP3573A (en) Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
PL2020864T3 (pl) Sprasowana guma do żucia i sposób jej wytwarzania
SI1608346T1 (sl) Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
TN2011000261A1 (en) Octreotide depot formulation with constantly high exposure levels
WO2009117401A3 (en) Compositions for site-specific delivery of imatinib and methods of use
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
AR070593A1 (es) Composiciones efervescentes
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2007016315A3 (en) Extended release venlafaxine compositions
TW200833375A (en) Pharmaceutical compositions
TNSN08271A1 (en) Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
MX2010009500A (es) Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.
PT1889629E (pt) Formulação estável compreendendo uma associação de um fármaco sensível à humidade e de um segundo fármaco e processo para o seu fabrico

Legal Events

Date Code Title Description
FA Abandonment or withdrawal